Featured Research

from universities, journals, and other organizations

Drug Combination Slows Progression Of Treatment Resistant Bone Marrow Cancer

Date:
December 13, 2006
Source:
University of North Carolina School of Medicine
Summary:
Combining a newly formulated drug with one that is already a standard treatment slows the progression of multiple myeloma, an advanced cancer of the bone marrow cells, according to a clinical trial led by a University of North Carolina at Chapel Hill School of Medicine researcher.

Combining a newly formulated drug with one that is already a standard treatment slows the progression of multiple myeloma, an advanced cancer of the bone marrow cells, according to a clinical trial led by a University of North Carolina at Chapel Hill School of Medicine researcher.

The phase III trial included 646 patients from 18 countries with relapsed or refractory multiple myeloma, a condition in which cancerous cells continue to multiply despite treatment. Patients in the trial were randomly assigned to receive the drug bortezomib (Velcade), standard therapy for relapsed multiple myeloma, or a combination of Velcade and Doxil, a chemotherapy drug (doxorubicin) delivered via liposomes, or microscopic fat bubbles.

An interim analysis of study participants who received the combination treatment showed a better response in the combination group than in participants who received standard treatment. The combination group's median time to progression - the time interval between the response to treatment and the time the disease starts to show evidence of growing or recurring - was 9.3 months, while those on Velcade alone progressed after 6.5 months.

The three-month improvement is an important step forward in treatment for multiple myeloma, said Dr. Robert Orlowski, Lenvel Lee Rothrock associate professor in the department of hematology/oncology at the School of Medicine, and a member of the UNC Lineberger Comprehensive Cancer Center.

Orlowski presented the trial's early results on Monday (Dec. 11), at the meeting of the American Society of Hematology in Orlando, Fla. The study was supported by Johnson & Johnson, which owns Ortho Biotech, the maker of Doxil, and also has a financial interest in Velcade.

"The data for time to progression were so positive and encouraging that we decided to announce this information earlier than anticipated so more people could be aware of the benefits of this combination," said Orlowski.

"This study establishes that this combination is one of the standards of care for relapsed, refractory multiple myeloma," Orlowski said. "It does provide some added hope for patients and their families."

The interim analysis also showed an early trend toward increased survival for patients taking the combination treatment, Orlowski said. Additional data on survival and the complete results of this analysis, as well as other factors such as quality of life, will be reported at a later date.

More than 11,000 people in the United States will die of multiple myeloma in 2006, according to the American Cancer Society. Because it affects white blood cells, multiple myeloma suppresses the immune system, so patients can develop sometimes-fatal infections. Other complications include kidney failure, bone pain, anemia, and bleeding.

Doxil is a liposmal version of an older drug, doxorubicin, which means the drug is encapsulated in a microscopic pouch made of lipids, or fats. The formulation seems to produce fewer cardiac side effects and is more convenient to administer.

Orlowski and others first found that doxorubicin and Doxil may complement Velcade in studies of cells in culture, and of mice. "We've been able to take findings from the laboratory and move them on to patients in early, phase I clinical trials, and now in this phase III trial," Orlowski said. "It's an excellent example of how support of basic and translational laboratory research can, in a short time period, result in tangible benefits to patients."

Other investigators were Sen H. Zhuang, Trilok Parekh and Liang Xiu, all of Johnson and & Johnson Pharmaceutical Research & Development, and Jean-Luc Harousseau of University Hospital Hotel-Dieu, Nantes, France.


Story Source:

The above story is based on materials provided by University of North Carolina School of Medicine. Note: Materials may be edited for content and length.


Cite This Page:

University of North Carolina School of Medicine. "Drug Combination Slows Progression Of Treatment Resistant Bone Marrow Cancer." ScienceDaily. ScienceDaily, 13 December 2006. <www.sciencedaily.com/releases/2006/12/061212213729.htm>.
University of North Carolina School of Medicine. (2006, December 13). Drug Combination Slows Progression Of Treatment Resistant Bone Marrow Cancer. ScienceDaily. Retrieved September 23, 2014 from www.sciencedaily.com/releases/2006/12/061212213729.htm
University of North Carolina School of Medicine. "Drug Combination Slows Progression Of Treatment Resistant Bone Marrow Cancer." ScienceDaily. www.sciencedaily.com/releases/2006/12/061212213729.htm (accessed September 23, 2014).

Share This



More Health & Medicine News

Tuesday, September 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Costs Keep Mounting

Ebola Costs Keep Mounting

Reuters - Business Video Online (Sep. 23, 2014) The WHO has warned up to 20,000 people could be infected with Ebola over the next few weeks. As Sonia Legg reports, the implications for the West African countries suffering from the disease are huge. Video provided by Reuters
Powered by NewsLook.com
Ebola Cases Could Reach 1.4 Million Within 4 Months

Ebola Cases Could Reach 1.4 Million Within 4 Months

Newsy (Sep. 23, 2014) Health officials warn that without further intervention, the number of Ebola cases in Liberia and Sierra Leone could reach 1.4 million by January. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Cases to Triple in Weeks Without Drastic Action

WHO: Ebola Cases to Triple in Weeks Without Drastic Action

AFP (Sep. 23, 2014) The number of Ebola infections will triple to 20,000 by November, soaring by thousands every week if efforts to stop the outbreak are not stepped up radically, the WHO warned in a study on Tuesday. Duration: 01:01 Video provided by AFP
Powered by NewsLook.com
5 Ways Men Can Prevent Most Heart Attacks

5 Ways Men Can Prevent Most Heart Attacks

Newsy (Sep. 23, 2014) No surprise here: A recent study says men can reduce their risk of heart attack by maintaining a healthy lifestyle, which includes daily exercise. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins